Citations

Showing 10 of 108104 citations.

Myeloid Sarcoma of the Temporal Bone: A Unique Cause of Hearing Loss, Otalgia, and Facial Nerve Weakness
Zheng, Henry D. , Abdel‐Aty, Yassmeen , Taylor, Cullen A., Engholdt, Jaime, Robetorye, Ryan S. , Marks, Lisa , Weisskopf, Peter A., Taylor, Cullen , Marks, Lisa A , Hoxworth, Joseph M.

Mayo Clinic

Otology & Neurotology | February 4, 2022 | Volume: 43 | Issue: 4 | Pages: e435-e441

10.1097/mao.0000000000003478 | PMID 35120076 Get It

Objective: To characterize a clinical triad of symptoms associated with myeloid sarcomas of the temporal bone via a review of all previously reported cases. Methods: Case report and Ovid MEDLINE database literature review. Results: A literature search revealed that a clinical triad of hearing loss, otalgia, and facial nerve weakness are commonly associated with this rare presentation of myeloid sarcoma in the temporal bone. 44% (18/41) of patients presented with all three symptoms, while 76% (31/41) presented with at least two. The presence of t(8;21) was reported in nine patients with myeloid sarcomas of the temporal bone. Conclusions: Although myeloid sarcomas are exceedingly rare, it is necessary to consider them as part of the differential diagnosis for patients who might present with middle ear and mastoid opacification on computed tomography (CT) scan, hearing loss, otalgia, and facial nerve palsy. Physicians should maintain a high degree of suspicion in patients with a history of acute myelogenous leukemia (AML), especially if previous cytogenetic analysis revealed a t(8;21).
Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study
Schregel, Ida , Eaton, John E. , Jones, Randall, Ramos, GuilhermePiovezani, Ioannou, Stephanie , Chazouillères, Olivier , Joshi, Deepak , Zigmond, Ehud , Shibolet, Oren , Zhou, Taotao , Ramos, Guilherme Piovezani , Levy, Cynthia , Culver, Emma , Färkkilâ, Martti , Müller, Tobias , Nayagam, Jeremy Shanika , Drenth, Joost P.H. , Hoentjen, Frank , Geerts, Anja M. , Weismüller, Tobias J. , Schramm, Christoph

Mayo Clinic

Zeitschrift für Gastroenterologie | February 4, 2022 | Volume: 60 | Issue: 01 | Pages: e18-e18

10.1055/s-0041-1740704 Get It

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma
Cantor, Evan , Wierzbicki, Kyle , Ravi, Karthik , Thomas, Chase, Cartaxo, Rodrigo T. , Yadav, Viveka Nand , Ravindran, Ramya , Bruzek, Amy K., Wadden, Jack , John, Vishal , Babila, Clarissa May, Cummings, Jessica, Ramos, Johanna, Paul, Alyssa , Walling, Dustin , Leonard, Marcia, Robertson, Patricia L. , Franson, Andrea , Mody, Rajen , Garton, Hugh , Venneti, Sriram , Odia, Yazmín , Kline, Cassie , Vitanza, Nicholas A. , Khatua, Soumen , Mueller, Sabine , Allen, Joshua E. , Mueller, Sabine , Koschmann, Carl , Franson, Andrea , Ravi, Karthik , Yadav, Viveka N , Odia, Yazmin , Tarapore, Rohinton S. , Kawakibi, Abed Rahman , Ji, Sunjong , Gardner, Sharon L , Koschmann, Carl

Mayo Clinic

Neuro-Oncology | February 4, 2022 | Volume: 24 | Issue: 8 | Pages: 1366-1374

10.1093/neuonc/noac030 | PMID 35137228 Get It

Abstract Background Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal childhood brain cancer, with patients rarely surviving 2 years from diagnosis. Methods We conducted a multi-site Phase 1 trial of the imipridone ONC201 for children with H3K27M-mutant glioma (NCT03416530). Patients enrolled on Arm D of the trial (n = 24) underwent serial lumbar puncture for cell-free tumor DNA (cf-tDNA) analysis and patients on all arms at the University of Michigan underwent serial plasma collection. We performed digital droplet polymerase chain reaction (ddPCR) analysis of cf-tDNA samples and compared variant allele fraction (VAF) to radiographic change (maximal 2D tumor area on MRI). Results Change in H3.3K27M VAF over time (“VAF delta”) correlated with prolonged PFS in both CSF and plasma samples. Nonrecurrent patients that had a decrease in CSF VAF displayed a longer progression free survival (P = .0042). Decrease in plasma VAF displayed a similar trend (P = .085). VAF “spikes” (increase of at least 25%) preceded tumor progression in 8/16 cases (50%) in plasma and 5/11 cases (45.4%) in CSF. In individual cases, early reduction in H3K27M VAF predicted long-term clinical response (>1 year) to ONC201, and did not increase in cases of later-defined pseudo-progression. Conclusion Our work demonstrates the feasibility and potential utility of serial cf-tDNA in both plasma and CSF of DMG patients to supplement radiographic monitoring. Patterns of change in H3K27M VAF over time demonstrate clinical utility in terms of predicting progression and sustained response and possible differentiation of pseudo-progression and pseudo-response.
CT Fractional Flow Reserve: A Practical Guide to Application, Interpretation, and Problem Solving
Rajiah, Prabhakar , Cummings, Kristopher W. , Williamson, Eric E. , Young, Phillip M. , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | February 4, 2022 | Volume: 42 | Issue: 2 | Pages: 340-358

10.1148/rg.210097 | PMID 35119968 Get It

Sex-related brain connectivity correlates of compensation in adults with autism: insights into female protection
Walsh, Melissa , Pagni, Broc A. , Monahan, Leanna , Delaney, Shanna , Smith, Christopher J. , Baxter, Leslie C. , Braden, B. Blair , Walsh, Melissa J M , Pagni, Broc , Baxter, Leslie C.

Mayo Clinic

Cerebral Cortex | February 4, 2022 | Volume: 33 | Issue: 2 | Pages: 316-329

10.1093/cercor/bhac069 | PMID 35212373 Get It

AbstractThe male preponderance in autism spectrum disorder (ASD) led to the hypothesis that aspects of female biology are protective against ASD. Females with ASD (ASD-F) report more compensatory behaviors (i.e. “camouflaging”) to overcome ASD-related social differences, which may be a mechanism of protection. No studies have examined sex-related brain pathways supporting camouflaging in ASD-F, despite its potential to inform mechanisms underlying the ASD sex bias. We used functional connectivity (FC) to investigate “sex-atypical” and “sex-typical” FC patterns linked to camouflaging in adults with ASD and examined multimodal coherence of findings via structural connectometry. Exploratory associations with cognitive/emotional functioning examined the adaptive nature of FC patterns. We found (i) “sex-atypical” FC patterns linked to camouflaging in the hypothalamus and precuneus and (ii) “sex-typical” patterns in the right anterior cingulate and anterior parahippocampus. Higher hypothalamic FC with a limbic reward cluster also correlated with better cognitive control/emotion recognition. Structural connectometry validated FC results with consistent brain pathways/effect patterns implicated in ASD-F. In summary, “male-typical” and “female-typical” brain connectivity patterns support camouflaging in ASD-F in circuits implicated in reward, emotion, and memory retrieval. “Sex-atypical” results are consistent with fetal steroidogenic/neuroinflammatory hypotheses. However, female genetics/biology may contribute to “female-typical” patterns implicated in camouflaging.
The COX-2–PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas
Wei, Jie, Zhang, Jinyu, Wang, Dingzhi, Cen, Bo, Lang, Jessica D. , DuBois, Raymond N., Wei, Jie, Zhang, Jinyu, Wang, Dingzhi, Cen, Bo, Lang, Jessica D. , DuBois, Raymond N.

Mayo Clinic

Cancer Prevention Research | February 4, 2022 | Volume: 15 | Issue: 5 | Pages: 285-296

10.1158/1940-6207.capr-21-0572 | PMID 35121582 Get It

Abstract The mechanisms underlying the regulation of a checkpoint receptor, PD-1, in tumor-infiltrating immune cells during the development of colorectal cancer are not fully understood. Here we demonstrate that COX-2–derived PGE2, an inflammatory mediator and tumor promoter, induces PD-1 expression by enhancing NFκB's binding to the PD-1 promoter via an EP4–PI3K–Akt signaling pathway in both CD8+ T cells and macrophages. Moreover, PGE2 suppresses CD8+ T-cell proliferation and cytotoxicity against tumor cells and impairs macrophage phagocytosis of cancer cells via an EP4–PI3K–Akt–NFκB–PD-1 signaling pathway. In contrast, inhibiting the COX-2–PGE2–EP4 pathway increases intestinal CD8+ T-cell activation and proliferation and enhances intestinal macrophage phagocytosis of carcinoma cells accompanied by reduction of PD-1 expression in intestinal CD8+ T cells and macrophages in ApcMin/+ mice. PD-1 expression correlates well with COX-2 levels in human colorectal cancer specimens. Both elevated PD-1 and COX-2 are associated with poorer overall survival in patients with colorectal cancer. Our results uncover a novel role of PGE2 in tumor immune evasion. They may provide the rationale for developing new therapeutic approaches to subvert this process by targeting immune checkpoint pathways using EP4 antagonists. In addition, our findings reveal a novel mechanism explaining how NSAIDs reduce colorectal cancer risk by suppressing tumor immune evasion. Prevention Relevance: These findings provide a potential explanation underlying the chemopreventive effect of NSAIDs on reducing colorectal cancer incidence during premalignancy and provide a rationale for developing EP4 antagonists for colorectal cancer prevention and treatment. Simply targeting PGE2 signaling alone may be efficacious in colorectal cancer prevention and treatment, avoiding side effects associated with NSAIDs.
Clinical evaluation and management of calcific tendinopathy: an evidence-based review
Robinson, David M. , Schowalter, Sean, McInnis, Kelly C. , Catapano, Michael , Robinson, David M

Mayo Clinic

Journal of Osteopathic Medicine | February 4, 2022 | Volume: 122 | Issue: 3 | Pages: 141-151

10.1515/jom-2021-0213 | PMID 35119231 Get It

Abstract Calcific tendinopathy (CT) is an important musculoskeletal condition most commonly seen in the shoulder girdle, accounting for 10–42% of all shoulder pain. Despite the high prevalence within the shoulder region, CT has been demonstrated in many tendons throughout the axial and appendicular skeleton. Unlike degenerative tendinopathies, CT appears to be a self-limiting condition that affects otherwise-healthy tendon with deposition of calcium hydroxyapatite crystals between healthy tenocytes. In patients with functionally limiting symptoms or pain, the clinical course may be accelerated through a multitude of treatments including physical therapy and pain management, extracorporeal shock wave therapy, ultrasound-guided percutaneous lavage (UGPL), and operative debridement. Currently, the most efficacious and frequently utilized treatment for shoulder CT is UGPL due to its ability to effectively reduce calcium burden and pain while limiting soft-tissue damage. However, more evidence regarding the treatment and course of CT is needed before determining the most appropriate treatment at all potential sites of CT.
Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort
Palmowski, Andriko , Wiebe, Edgar , Muche, Burkhard , Hermann, Sandra , Dejaco, Christian , Matteson, Eric L. , Buttgereit, Frank , Dejaco, Christian , Buttgereit, Frank

Mayo Clinic

Cells | February 4, 2022 | Volume: 11 | Issue: 3 | Pages: 536

10.3390/cells11030536 | PMID 35159345 Get It

Background: Glucocorticoids (GCs) can cause osteoporosis (OP). Prior observational research on bone density and the effects of GCs in polymyalgia rheumatica (PMR) and vasculitides is scarce and inconclusive. Methods: Rh-GIOP is a prospective cohort study of bone health in patients with inflammatory rheumatic diseases. In this cross-sectional baseline analysis, we focused on patients with PMR and different forms of vasculitides. Multivariable linear regression was used to model the effect of current and cumulative GC intake on the minimum T-score at any site (mTs; at either lumbar spine or hip), with comprehensive adjustment for confounders. In separate models, GCs were modelled both as continuous and categorical predictors. Sensitivity analyses, stratifying by measurement site and disease, were conducted. Results: A total of 198 patients, with a mean age of 67.7 ± 11.4 years and a mean disease duration of 5.3 ± 6.3 years, were included. Most patients suffered from PMR (36%), giant cell arteritis (26%) or granulomatosis with polyangiitis (17%). Women comprised 66.7% of the patients, and 87.4% were currently taking GCs. The mean CRP was 13.2 ± 26.1 mg/L. OP diagnosed by dual energy X-ray absorptiometry (DXA) (T-score ≤ −2.5) was present in 19.7% of the patients. While 88% were taking vitamin D supplements, calcium supplementation (4%) and treatment with anti-resorptive agents (17%) were relatively infrequent. Only 7% had a vitamin D deficit. Neither current (β(continuous model) = −0.01, 97.5% CI –0.02 to 0.01; p(all models) ≥ 0.49) nor cumulative (β(continuous model) = 0.01, 97.5% CI −0.04 to 0.07; p(all models) ≥ 0.35) GC doses were associated with mTs in any model. CRP was not associated with mTs in any model (p(all models) ≥ 0.56), and no interaction between CRP and GC intake was observed (p for interaction(all models) ≥ 0.32). Across all analyses, lower body mass index (p(all models) ≤ 0.01), history of vertebral fractures (p(all models) ≤ 0.02) and proton-pump inhibitor intake (p(all models) ≤ 0.04) were associated with bone loss. Sensitivity analyses with femoral neck and lumbar spine T-scores as dependent variables led to similar results as the analysis that excluded patients with PMR. Conclusions: In this cohort of PMR and vasculitides, we found a similar prevalence of OP by DXA to the overall elderly German population. Vitamin D supplementation was very common, and vitamin D insufficiency was less frequent than expected in Germans. There was no association between current or cumulative GC intake, CRP and impaired bone density. Proton-pump inhibitors seem to be a major, but somewhat neglected, risk factor for OP and should be given more attention. Our findings require confirmation from longitudinal analyses of the Rh-GIOP and other cohorts.
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, Kristin S. , Buzhardt, Michele Scotti , Leitges, Michael , Krishna, Murli , Fields, Alan P. , Murray, Nicole R. , Scotti Buzhardt, Michele L , Leitges, Michael , Crawford, Howard C, Liu, Yi Sha , Crawford, Howard C.

Mayo Clinic

Cancers | February 4, 2022 | Volume: 14 | Issue: 3 | Pages: 796

10.3390/cancers14030796 | PMID 35159064 Get It

Protein kinase C iota (PKCι) functions as a bonafide human oncogene in lung and ovarian cancer and is required for KrasG12D-mediated lung cancer initiation and progression. PKCι expression is required for pancreatic cancer cell growth and maintenance of the transformed phenotype; however, nothing is known about the role of PKCι in pancreas development or pancreatic tumorigenesis. In this study, we investigated the effect of pancreas-specific ablation of PKCι expression on pancreatic cellular homeostasis, susceptibility to pancreatitis, and KrasG12D-mediated pancreatic cancer development. Knockout of pancreatic Prkci significantly increased pancreatic immune cell infiltration, acinar cell DNA damage, and apoptosis, but reduced sensitivity to caerulein-induced pancreatitis. Prkci-ablated pancreatic acinar cells exhibited P62 aggregation and a loss of autophagic vesicles. Loss of pancreatic Prkci promoted KrasG12D-mediated pancreatic intraepithelial neoplasia formation but blocked progression to adenocarcinoma, consistent with disruption of autophagy. Our results reveal a novel promotive role for PKCι in pancreatic epithelial cell autophagy and pancreatic cancer progression.
Safety of catheter ablation in obese patients: Less complicated than you think
Kowlgi, Gurukripa N. , Siontis, Konstantinos C. , Kowlgi, Narayan G

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 4, 2022 | Volume: 33 | Issue: 4 | Pages: 664-666

10.1111/jce.15394 | PMID 35118744 Get It